{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:46:12Z","timestamp":1789526772101,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/med.0b013e32835056d4","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T16:06:45Z","timestamp":1377878805000},"page":"109-114","source":"Crossref","is-referenced-by-count":25,"title":["Apolipoprotein A-I mimetics and high-density lipoprotein function"],"prefix":"10.1097","volume":"19","author":[{"given":"Scott M.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20211004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tem.2010.10.001","article-title":"High density lipoprotein: its not just about lipid transport anymore.","volume":"22","author":"Gordon","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"R2-8-20211004","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2010.12.003","article-title":"Apolipoprotein mimetic peptides: mechanisms of action as antiatherogenic agents.","volume":"130","author":"Osei-Hwedieh","year":"2011","journal-title":"Pharmacol Ther"},{"key":"R3-8-20211004","doi-asserted-by":"crossref","first-page":"32273","DOI":"10.1074\/jbc.M804461200","article-title":"Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.","volume":"283","author":"Sethi","year":"2008","journal-title":"J Biol Chem"},{"key":"R4-8-20211004","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1124\/jpet.110.167890","article-title":"5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.","volume":"334","author":"Amar","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R5-8-20211004","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2011.05.029","article-title":"Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptidephospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits.","volume":"218","author":"Iwata","year":"2011","journal-title":"Atherosclerosis"},{"key":"R6-8-20211004","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCRESAHA.110.216507","article-title":"Structurefunction relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.","volume":"107","author":"DSouza","year":"2010","journal-title":"Circ Res"},{"key":"R7-8-20211004","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbrc.2011.05.154","article-title":"Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter.","volume":"410","author":"Sviridov","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"R8-8-20211004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":"Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"R9-8-20211004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.atherosclerosis.2011.04.001","article-title":"The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins.","volume":"217","author":"Di Bartolo","year":"2011","journal-title":"Atherosclerosis"},{"key":"R10-8-20211004","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/01.CIR.0000159351.95399.50","article-title":"Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits.","volume":"111","author":"Nicholls","year":"2005","journal-title":"Circulation"},{"key":"R11-8-20211004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-511X-10-35","article-title":"HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.","volume":"10","author":"Kelesidis","year":"2011","journal-title":"Lipids Health Dis"},{"key":"R12-8-20211004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000316479","article-title":"ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta.","volume":"32","author":"Vaziri","year":"2010","journal-title":"Am J Nephrol"},{"key":"R13-8-20211004","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/ijc.26079","article-title":"D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.","volume":"130","author":"Ganapathy","year":"2012","journal-title":"Int J Cancer"},{"key":"R14-8-20211004","doi-asserted-by":"crossref","first-page":"19997","DOI":"10.1073\/pnas.1009010107","article-title":"Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.","volume":"107","author":"Su","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R15-8-20211004","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1039\/c0ib00147c","article-title":"L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGFbasic FGF signaling pathways.","volume":"3","author":"Gao","year":"2011","journal-title":"Integr Biol (Camb)"},{"key":"R16-8-20211004","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4049\/jimmunol.1001534","article-title":"5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma.","volume":"186","author":"Yao","year":"2011","journal-title":"J Immunol"},{"key":"R17-8-20211004","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1194\/jlr.M008086","article-title":"The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats.","volume":"51","author":"Dai","year":"2010","journal-title":"J Lipid Res"},{"key":"R18-8-20211004","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1194\/jlr.M800075-JLR200","article-title":"Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.","volume":"49","author":"van Lenten","year":"2008","journal-title":"J Lipid Res"},{"key":"R19-8-20211004","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3020","article-title":"Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.","volume":"12","author":"Woo","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R20-8-20211004","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.2337\/db10-0844","article-title":"Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes.","volume":"59","author":"Morgantini","year":"2010","journal-title":"Diabetes"},{"key":"R21-8-20211004","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1194\/jlr.M800046-JLR200","article-title":"L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.","volume":"49","author":"Peterson","year":"2008","journal-title":"J Lipid Res"},{"key":"R22-8-20211004","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/jcb.23188","article-title":"Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice.","volume":"112","author":"Vecoli","year":"2011","journal-title":"J Cell Biochem"},{"key":"R23-8-20211004","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1194\/jlr.M013144","article-title":"Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally.","volume":"52","author":"Navab","year":"2011","journal-title":"J Lipid Res"},{"key":"R24-8-20211004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1194\/jlr.M011098","article-title":"Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.","volume":"52","author":"Watson","year":"2011","journal-title":"J Lipid Res"},{"key":"R25-8-20211004","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.","volume":"49","author":"Bloedon","year":"2008","journal-title":"J Lipid Res"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201204000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T01:44:06Z","timestamp":1633311846000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201204000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0b013e32835056d4","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}